AARTIPHARM vs SUNPHARMA: Stock Comparison

AARTI PHARMALABS vs SUN PHARMACEUTICAL IND LUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. AARTI PHARMALABS shows a lower P/E and lower leverage, while SUN PHARMACEUTICAL IND L shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIPHARM leads 3; SUNPHARMA leads 10 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIPHARMSUNPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹7,812 Cr
₹4.56 L Cr
P/E RatioAARTIPHARM has the lower reading
36.83x
38.35x
P/B RatioAARTIPHARM has the lower reading
3.71x
5.55x
EPSSUNPHARMA has the higher reading
₹8.4
₹50.42
Book ValueContext only
₹234.3
₹348.31
Dividend YieldSUNPHARMA has the higher reading
0.46%
0.83%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.56 L Cr vs ₹7,812 Cr
P/E Ratio
AARTIPHARM has a lower P/E
36.83x vs 38.35x
P/B Ratio
AARTIPHARM has a lower P/B
3.71x vs 5.55x
EPS
SUNPHARMA has higher earnings per share
₹50.42 vs ₹8.4
Dividend Yield
SUNPHARMA has a higher dividend yield
0.83% vs 0.46%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs 3.3%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs -30.8%
Qtr Sales Growth
SUNPHARMA has stronger quarterly sales growth
166.5% vs 0.23%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIPHARMSUNPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIPHARMSUNPHARMA
Live Price₹858.8₹1,899
Day Change-1.07%-0.89%
Volume4.63 L7.61 L
52-Week High₹946.1₹2,046.9
52-Week Low₹585₹1,548
Distance from 52W High-9.23%-7.23%

Valuation

MetricAARTIPHARMSUNPHARMA
Market Cap₹7,812 Cr₹4.56 L Cr
P/E Ratio36.83x38.35x
P/B Ratio3.71x5.55x
EPS₹8.4₹50.42
Book Value₹234.3₹348.31
Dividend Yield0.46%0.83%

Growth

MetricAARTIPHARMSUNPHARMA
Revenue Growth (TTM YoY)3.3%12.8%
EPS Growth (TTM YoY)-30.8%25.6%
Qtr Sales Growth0.23%166.5%
Qtr Profit Growth6.78%160.17%

Profitability & Leverage

MetricAARTIPHARMSUNPHARMA
ROE9.48%11.76%
ROCE8.38%9.6%
Net Margin10.25%18.56%
Operating Margin16.52%22.81%
Debt to Equity0.35x0.6x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIPHARMSUNPHARMA
Promoter Holding42.69% 0.22 pp54.48%
FII Holding8.17% 0.22 pp14.53% 1.4 pp
DII Holding7.22% 0.19 pp22.18% 1.07 pp
Public Holding41.74% 0.63 pp8.81% 0.33 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI PHARMALABS and SUN PHARMACEUTICAL IND L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.